News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 28, 2014, 13:24 ET
IMBRUVICA(R) (ibrutinib) 140mg capsules. (PRNewsFoto/Janssen Biotech, Inc.)

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for...

Jul 27, 2014, 16:28 ET

Janssen recibe la opinión positiva del CHMP sobre IMBRUVICA™

- Janssen recibe la opinión positiva del CHMP: se recomienda IMBRUVICA™ para su uso en el tratamiento de dos formas de cáncer...

Jul 27, 2014, 08:51 ET

Janssen reçoit un avis positif du CHMP recommandant l'utilisation d'IMBRUVICA™ dans le traitement de deux formes de cancer du sang

Janssen-Cilag International NV (Janssen) a annoncé aujourd'hui que le Comité des médicaments à usage humain (CHMP) de l'Agence...

Jul 27, 2014, 07:55 ET

Janssen erhält positive Meinungsäußerung des CHMP mit der Empfehlung von IMBRUVICA™ zum Einsatz bei der Behandlung von zwei Formen von Blutkrebs

Janssen-Cilag International NV (Janssen) gab heute bekannt, dass das Komitee für Medizinprodukte zur Anwendung am Menschen (Committee for...

Jul 25, 2014, 19:19 ET

El virus de la hepatitis C es la principal causa de los trasplantes de hígado en el mundo

 La División de Química, Alimentos y Medicamentos del Ministerio de Salud de Trinidad y Tobago aprobó la introducción de...

Jul 25, 2014, 11:16 ET

The Hepatitis C virus is the main cause of liver transplant in the world

 The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the...

Jul 14, 2014, 08:00 ET

Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies

 Janssen Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Jun 24, 2014, 06:58 ET

Fighting for Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts to Address Hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C...

Jun 18, 2014, 08:30 ET

Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for...

Jun 18, 2014, 07:59 ET

The Satisfaction Project challenges Canadians with psoriasis and psoriatic arthritis to take control and live better

~Expert panel shares tips, encouraging patients to take a 360° approach to managing their disease and to not give up until they're...

Jun 16, 2014, 17:00 ET

New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies

 Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term...

Jun 12, 2014, 06:00 ET

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and...

Jun 10, 2014, 08:56 ET

Janssen to Present Latest Data for Type 2 Diabetes Treatment INVOKANA® (canagliflozin) at American Diabetes Association 74th Scientific Sessions®

 Janssen Research & Development, LLC (Janssen) announced today that 15 presentations on INVOKANA® (canagliflozin) will be made at the...

Jun 05, 2014, 09:58 ET

La Comisión Europea aprueba SYLVANT® (siltuximab) como tratamiento para la enfermedad de Castleman multicéntrica (MCD)

  - La Comisión Europea aprueba SYLVANT® (siltuximab) como tratamiento para los pacientes con enfermedad de Castleman...

Jun 05, 2014, 09:31 ET

La Commission Européenne approuve l'utilisation du SYLVANT® (siltuximab) dans le traitement de la maladie de Castleman multicentrique (MCM)

  Premier traitement approuvé en Europe pour la prise en charge de la MCM        Janssen-Cilag...

Jun 05, 2014, 09:28 ET

Die Europäische Kommission erteilt die Zulassung für SYLVANT® (Siltuximab) zur Behandlung von Patienten mit der multizentrischen Castleman-Krankheit (MCD)

  Erste Behandlung für das Management von MCD in Europa zugelassen    Janssen-Cilag International NV ("Janssen") gab heute...

Jun 02, 2014, 08:30 ET

IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)

 Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary...

May 31, 2014, 07:33 ET
May 31, 2014, 07:31 ET

Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia

Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA®) suggest continued durable responses in...

May 14, 2014, 17:12 ET

Janssen to Showcase Growing Body of Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50th Annual...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets